ORGANIZATION

The March of Dimes

The public fundraising organization — founded by Franklin D. Roosevelt in 1938 as the National Foundation for Infantile Paralysis — that funded the research, the field trials, and the production of Salk's polio vaccine through small donations from millions of ordinary Americans.

The March of Dimes was one of the most successful public health fundraising efforts in American history, and it made Salk's work possible in a specific institutional sense: it provided sustained, patient funding for research that no commercial entity would have financed on the timescale required. Roosevelt founded the organization in 1938 under its original name, the National Foundation for Infantile Paralysis, drawing on his own experience as a polio survivor. The name 'March of Dimes' — coined by entertainer Eddie Cantor — referred to the fundraising model: small donations (often literal dimes) from ordinary citizens, accumulating into one of the largest medical research funds of the twentieth century. By the early 1950s, the Foundation was funding the basic virology research that made the vaccine possible, the 1954 field trials that tested it, and the rapid production and distribution that followed the 1955 announcement.

In The You On AI Encyclopedia

The organization's funding model was itself an Epoch B phenomenon: millions of individual Americans contributing small amounts toward a shared long-term goal, trusting institutional stewardship across decades. The model demonstrated that large-scale cooperation on long time horizons was possible when the right institutional architecture existed.

Salk's relationship with the Foundation was central to his career. The Foundation funded his laboratory at the University of Pittsburgh beginning in 1948. It sponsored the 1954 field trials — the largest public health experiment in American history — which tested the vaccine on 1.8 million children. It coordinated the announcement of the vaccine's efficacy on April 12, 1955. And it funded the initial production and distribution that ended the epidemic.

The Foundation's role illustrates a principle Salk emphasized repeatedly: major biomedical advances require institutional scaffolding that the market alone will not provide. Basic virology research in the 1940s had no commercial application. Field trials on 1.8 million children could not have been organized or funded by any pharmaceutical company. The vaccine's successful development required sustained public investment across more than a decade, and that investment was possible only because of the unique institutional form the Foundation had created.

The organization still exists, having shifted its mission after polio's effective elimination to focus on birth defects, premature birth, and maternal health. Its trajectory — from single-disease focus to broader public health mission — illustrates the institutional logic Salk admired: structures designed for specific purposes that remain capable of serving successor purposes when the original challenge is met.

Key Ideas

Patient capital enables long research. The Foundation's willingness to fund basic research for a decade before any commercial application was possible was the institutional precondition of the vaccine.

Small donations, vast aggregation. The funding model demonstrated that ordinary citizens could coordinate at scale toward long-term shared goals.

Salk's relationship with the Foundation was central to his career

Institutional infrastructure is necessary. The vaccine required not just scientific breakthrough but field trials, production, and distribution — all of which depended on organizational capacity the market would not have produced.

Trust across decades. The Foundation's success required Americans to trust institutional stewardship across generations — a trust that is structurally difficult to establish and easy to destroy.

In The You On AI Encyclopedia

Key Ideas

Related Entries

Further Reading